From Wikipedia, the free encyclopedia
Jump to: navigation, search
Zymogenetics headquarters, as viewed from Lake Union in Seattle, Washington

ZymoGenetics, Inc is a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters is 1201 Eastlake Avenue East.

The company was founded in 1981 by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia. Soon after its founding, ZymoGenetics began working on recombinant proteins with Danish company Novo Nordisk, and was acquired by that company in 1988. It was spun off as a public company in 2000. Bristol-Myers Squibb acquired the company in 2010.

ZymoGenetics' headquarters are in the landmark Lake Union Steam Plant building, built from 1914 to 1921 by Seattle City Light, the municipal electric utility.

Corporate governance[edit]

In late 2013, the company's president, Stephen W. Zaruby, left and took up the president and chief executive officer roles at Aurinia Pharmaceuticals.[1]


  1. ^ Slatko, Joshua (December 2013). "BMS changes senior management team". People on the Move: Biopharma. Med Ad News. p. 27. 

External links[edit]